Status: Not yet recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).
Participants needed: 174
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Henlius BiotechUpdated: Apr 15, 2026
Eligibility criteria
Participants must have signed and dated an IRB/IEC approved written informed con... [+11]
History of illicit drug use or alcohol abuse within 12 months prior to randomiza... [+15]